Condition: Polycythemia Vera (PV) · Sponsor: Disc Medicine, Inc
This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).
This description comes directly from the study's public registry record.
Disc Medicine Clinical Trials · (617) 674 9274 · clinicaltrials@discmedicine.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Phoenix, Arizona, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UCLA Health | Los Angeles, California, United States | Recruiting |
| Keck Medicine of USC - Cancer Clinic- Newport Beach | Newport Beach, California, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic in Minnesota | Rochester, Minnesota, United States | Recruiting |
| Siteman Cancer Center - Washington University St. Louis | St Louis, Missouri, United States | Recruiting |
| Atrium Health - Levine Cancer Center | Charlotte, North Carolina, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Atrium Health Wake Forest Baptist Medical Center | Winston-Salem, North Carolina, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06985147